AAAAAA

   
Results: 1-25 | 26-32 |
Results: 26-32/32
Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level
Authors: Gahn, B Wendenburg, B Troff, C Neef, J Grove, D Haferlach, T Hiddemann, W Wormann, B
Citation: B. Gahn et al., Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level, BR J HAEM, 105(4), 1999, pp. 955-959
Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome
Authors: Griesinger, F Piro-Noack, M Kaib, N Falk, M Renziehausen, A Troff, C Grove, D Schnittger, S Buchner, T Ritter, J Hiddemann, W Wormann, B
Citation: F. Griesinger et al., Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome, BR J HAEM, 105(1), 1999, pp. 241-255
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus
Authors: Reich, K Brinck, U Letschert, M Blaschke, V Dames, K Braess, J Wormann, B Runger, TM Neumann, C
Citation: K. Reich et al., Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus, BR J DERM, 141(4), 1999, pp. 739-746
Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
Authors: Buchner, T Wormann, B Loffler, H Gassmann, W Haferlach, T Fonatsch, C Haase, D Schoch, C Hossfeld, D Lengfelder, E Aul, C Heyll, A Maschmeyer, G Ludwig, WD Sauerland, MC Heinecke, A
Citation: T. Buchner et al., Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group, BLOOD, 93(12), 1999, pp. 4116-4124
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide andetoposide): An effective and well-tolerated new regimen for patients with relapsed lymphoma
Authors: Reiser, M Schnell, R Straub, G Borchmann, P Wilhelm, M Ubelacker, R Wormann, B Munch, R Diehl, V Engert, A
Citation: M. Reiser et al., DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide andetoposide): An effective and well-tolerated new regimen for patients with relapsed lymphoma, LEUK LYMPH, 31(3-4), 1998, pp. 359-366
Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer
Authors: Herse, B Dalichau, H Wormann, B Hemmerlein, B Schmidberger, H Hess, CF Hannemann, P Criee, CP Hiddemann, W Griesinger, F
Citation: B. Herse et al., Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer, THOR CARD S, 46(5), 1998, pp. 298-302
High-dose therapy with stem-cell transplantation
Authors: Wormann, B
Citation: B. Wormann, High-dose therapy with stem-cell transplantation, INTERNIST, 39(11), 1998, pp. 1115-1122
Risultati: 1-25 | 26-32 |